肺腺癌治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Lung Adenocarcinoma Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月29日 | 出版商:

Global Market Insights Inc. | 英文 250 Pages | 商品交期: 2-3个工作天内

价格

简介目录

受肺癌（尤其是肺腺癌）发病率上升的推动，全球肺腺癌治疗市场将于 2023 年扩大至 51 亿美元，2024 年至 2032 年将以 10.5% 的复合年增长率增长。吸烟率、污染率和遗传倾向的增加导致了这一上升趋势。此外，标靶治疗的创新可提高治疗效果和患者预后，解决与腺癌相关的特定基因突变问题。这些进步提供了更个人化的治疗选择，并提高了存活率。随着人们对这些疗法的认识不断增强，它们吸引了更多患者，进一步扩大了这一关键领域的市场规模。

肺腺癌治疗产业根据治疗类型、疾病阶段、最终用途和地区而分散。

化疗领域将在 2023 年达到 19 亿美元，到 2032 年将以 10.2% 的复合年增长率增长，这得益于其广泛用于治疗晚期疾病。化疗仍然是一种标准治疗方法，通常单独使用或与免疫疗法或标靶治疗等其他疗法结合使用。即使在其他治疗失败的情况下，其在缩小肿瘤大小和控制疾病进展方面的有效性也巩固了其领先地位。药物配方的可及性增加和进步进一步促进了该细分市场的成长。

由于拥有先进的诊断和治疗设施，医院部门到 2024 年将获得 32 亿美元的收入，并在 2024 年至 2032 年实现 6.3% 的复合年增长率。医院通常是实施化疗、放疗和标靶治疗等复杂疗法的主要中心。此外，专业医疗保健专业人员的存在和管理重症病例的能力也有助于该细分市场的主导地位。肺癌患者数量的增加和医疗基础设施的改善进一步推动了该市场对医院治疗的需求。

由于完善的医疗基础设施和肺癌病例的高盛行率，到 2032 年，北美肺腺癌治疗市场将达到 57 亿美元。该地区受益于先进的医疗技术、创新的治疗方案以及对癌症研究的大力投资。此外，人们对早期诊断的认识不断提高，医疗保健服务的普及也提高了治疗效果。有利的报销政策和日益老化的人口进一步推动市场成长，使北美成为全球肺腺癌治疗产业的关键贡献者。

产业生态系统分析
产业影响力
- 成长动力
  - 肺腺癌盛行率增加
  - 精准医学和标靶治疗的进展
  - 提高认识和早期发现计划
- 产业陷阱与挑战
  - 治疗费用高
  - 不良反应和安全问题
成长潜力分析
监管环境
技术景观
管道分析
未来市场趋势
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

主要趋势
手术
放射治疗
化疗
标靶治疗
免疫疗法
其他治疗类型

第 6 章：市场估计与预测：按疾病阶段，2021 - 2032 年

主要趋势
第一阶段和第二阶段
第三阶段
第四阶段

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
专科诊所
其他最终用户

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson and Johnson Services, Inc.
Merck and Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited

简介目录

Product Code: 11125

The Global Lung Adenocarcinoma Treatment Market expanded to USD 5.1 billion in 2023 and will grow at 10.5% CAGR from 2024 to 2032, driven by the rising incidence of lung cancer, particularly lung adenocarcinoma. Increasing rates of smoking, pollution, and genetic predispositions contribute to this upward trend. Also, innovations in targeted therapies enhance treatment effectiveness and patient outcomes, addressing specific genetic mutations associated with adenocarcinoma. These advancements provide more personalized treatment options and lead to improved survival rates. As awareness of these therapies grows, they attract more patients, further expanding the market size in this critical area.

The lung adenocarcinoma treatment industry is fragmented based on treatment type, stages of disease, end-use, and region.

The chemotherapy segment will reach USD 1.9 billion in 2023 and grow at a 10.2% CAGR through 2032, fueled by its widespread use in managing advanced stages of the disease. Chemotherapy remains a standard treatment, often utilized alone or in combination with other therapies like immunotherapy or targeted treatments. Its effectiveness in reducing tumor size and controlling disease progression, even in cases where other treatments fail, solidifies its leading position. Increased accessibility and advancements in drug formulations further bolster the growth of this segment in the market.

The hospitals segment will secure USD 3.2 billion by 2024 and achieve a 6.3% CAGR from 2024 to 2032, owing to the availability of advanced diagnostic and treatment facilities. Hospitals are often the primary centers for administering complex therapies such as chemotherapy, radiation, and targeted treatments. Additionally, the presence of specialized healthcare professionals and the ability to manage severe cases contribute to the segment's dominance. The growing number of lung cancer patients and improved healthcare infrastructure further drive the demand for hospital-based treatments in this market.

North America lung adenocarcinoma treatment market will capture USD 5.7 billion by 2032, attributed to a well-established healthcare infrastructure and high prevalence of lung cancer cases. The region benefits from advanced medical technologies, innovative treatment options, and strong investment in cancer research. Also, rising awareness about early diagnosis and improved access to healthcare services enhance treatment outcomes. Favorable reimbursement policies and an increasing aging population further propel market growth, making North America a key contributor to the global lung adenocarcinoma treatment industry.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of lung adenocarcinoma
  - 3.2.1.2 Advances in precision medicine and targeted therapies
  - 3.2.1.3 Rising awareness and early detection programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatments
  - 3.2.2.2 Adverse effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Surgery
5.3 Radiation therapy
5.4 Chemotherapy
5.5 Targeted therapy
5.6 Immunotherapy
5.7 Other treatment types

Chapter 6 Market Estimates and Forecast, By Stage of Disease, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Stage I and II
6.3 Stage III
6.4 Stage IV

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa